
CNTA
Healthcare · Biotechnology · $6.27B market cap
Latest report
Time not confirmed
The next earnings date isn’t on the calendar yet.
Analyst consensus
Fiscal period ending Jun 30, 2026
EPS trend, 90 days to now · +0.4% over 90 days · 30-day revisions 2 up, 1 down
Beat estimates in 0 of the last 4 reported quarters.
EPS surprise versus the estimate at the time of the report.
| Date | Session | Estimate | Actual | Surprise |
|---|---|---|---|---|
| May 18, 2026 | Time not confirmed | -0.38 | -0.52 | -35.5% |
| Mar 26, 2026 | Time not confirmed | -0.38 | -0.48 | -24.9% |
| Nov 5, 2025 | Time not confirmed | -0.39 | -0.41 | -5.1% |
| Aug 12, 2025 | Time not confirmed | -0.33 | -0.38 | -15.3% |
| May 14, 2025 | Time not confirmed | -0.36 | -0.20 | +44.4% |
| Mar 24, 2025 | Time not confirmed | -0.42 | -0.84 | -100.0% |
| Nov 12, 2024 | Time not confirmed | -0.40 | -0.37 | +6.6% |
| Aug 13, 2024 | Time not confirmed | -0.39 | -0.40 | -2.6% |
| May 13, 2024 | After the close | -0.42 | -0.38 | +9.5% |
| Mar 28, 2024 | After the close | -0.48 | -0.38 | +20.8% |
| Nov 13, 2023 | After the close | -0.52 | -0.40 | +23.1% |
| Aug 14, 2023 | Before the open | -0.49 | -0.26 | +46.9% |
| May 12, 2023 | Before the open | -0.41 |
Centessa Pharmaceuticals plc, together with its subsidiaries, discovers, develops, and delivers orexin-based neuroscience therapeutics in the United Kingdom and the United States. The company develops ORX750, an orexin receptor 2 agonist, which is in Phase IIa clinical trial for the treatment of central disorders of hypersomnolence, including narcolepsy type 1 and 2, as well as idiopathic hypersomnia. It also…
| -0.53 |
| -29.3% |
| Mar 30, 2023 | Before the open | -0.48 | -0.45 | +6.3% |
| Nov 10, 2022 | Before the open | -0.56 | -0.57 | -1.8% |
| Aug 10, 2022 | Before the open | -0.57 | -0.69 | -21.1% |
| May 16, 2022 | Before the open | -0.70 | -0.60 | +14.3% |
| Mar 30, 2022 | After the close | -0.60 | -0.68 | -13.3% |
| Nov 15, 2021 | Before the open | -0.55 | -0.45 | +18.2% |
| Aug 16, 2021 | Before the open | -0.66 | -0.65 | +1.5% |
| Jun 1, 2021 | After the close | -0.32 | -0.12 | +62.5% |
| Mar 31, 2021 | Time not confirmed | 0.00 | -4.97 | — |